搜尋結果
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ), the virus that causes coronavirus disease 2019 ( COVID‑19 ). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing ...
- none
- Intramuscular
- mRNA, viral, inactivated, protein
- SARS-CoV-2
Skycovione is a COVID-19 vaccine candidate developed by SK Bioscience and the Institute for Protein Design of the University of Washington, [2] [3] [4] [5] [6] [7] [8] It is South Korea's first homegrown COVID-19 vaccine [9] and utilizes GSK 's AS03 adjuvant technology. The phase III clinical trial involves 4,037 participants.
- GBP510, Skycovion
- SARS-CoV-2
The COVID-19 pandemic, also known as the coronavirus pandemic, is a global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The novel virus was first identified in an outbreak in Wuhan, the capital of Hubei, China, in December 2019, before it spread to other areas of Asia, and then worldwide in early 2020.
- 6,956,160 (reported), 17.5–31.4 million (estimated)
- Worldwide
- Coronavirus disease 2019 (COVID-19)
- Severe acute respiratory syndromecoronavirus 2 (SARS‑CoV‑2)
- 新冠肺炎-疫苗資訊最前線
Timeline. Locations. International response. Medical response. Variants. Economic impact and recession. Impacts. COVID-19 portal. v. t. e. Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm. [1] [2]
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2.The first known case was identified in Wuhan, China, in December 2019. The disease quickly spread worldwide, resulting in the ongoing COVID-19 pandemic.The symptoms of COVID‑19 are variable but often include fever, fatigue, cough, breathing difficulties, loss of smell, and loss of taste.
- 6,960,770 (reported), 17.6–31.4 million (estimated)
- SARS-CoV-2
- 2–14 days (typically 5), after infection
- Symptomatic and supportive
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, [1] [2] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). [3] .
Covaxin (development name, BBV152) is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology. On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use, as the first Indian-developed covid vaccine to be approved.
